RNA Modifications
The delivery method and efficiency are the key factors for whether small nucleic acid drugs can enter cells and play a role. There are several delivery approaches, the naked RNA modification delivery technology, liposome nano-delivery technology, conjugated delivery system (small molecule ligands, antibodies, and other molecules), and other types of new delivery systems.
GenCefe Biotech provides comprehensive RNA modification, labeling, and conjugation services to meet the needs of different types of nucleic acid drug delivery. Backed by expertise and innovation, we're your partners in advancing research.
RNA Modifications:
| Modification Type | Modifications | Modification Type | Modifications |
| Point Modification | 2'OME | Special Modifications | Cholesterol |
| dspacer | GalNAc | ||
| dI | DBCO | ||
| rI | Desthiobiotin | ||
| dU | Cy5.5 | ||
| 2'F | Cy7 | ||
| 2'MOE | Hexynyl | ||
| LNA | BHQ1 | ||
| m6A | BHQ2 | ||
| m5C | BHQ3 | ||
| m5U | MGB | ||
| End Modifications | Thiol | ATTO Series | |
| Amino Linker | Chimeric RNA | DNA\RNA | |
| Biotin | RNA\2'F\2'OME\DNA | ||
| Phosphorylation | Dual-Labeling | FAM-BHQ1 | |
| spacer C9 | FAM-TAMRA | ||
| spacer C18 | FAM-Dab | ||
| Fluorescent Labeling | FAM | TAMRA-BHQ2 | |
| HEX | CY3-BHQ2 | ||
| Cy3 | CY5.5-BHQ3 | ||
| Cy5 | CY7-BHQ3 | ||
| TET | |||
| VIC | |||
| TAMRA |
Modifications for Small Nucleic Acid Drug:
Nucleic Acid Type | Chemical Modification and Fluorescent Labeling Services |
siRNA | Sugar Modification: 2'-Ome , 2'-F, etc. Backbone Modification: PS (phosphorothioate) modification, etc. E nd modification: Chol (cholesterol), Biotin, Thiol, NH 2 , etc. Fluorescent labeling: Cy3, Cy5, etc. Customized chemical modification and fluorescent labeling proposal design |
Antisense (ASO) | Sugar Modification: 2'-OMe, 2'-MOE, 2'-F, LNA, etc. Base Modification: methylated cytosine (5-Me-dC), etc. Backbone Modification: PS (phosphorothioate) modification, etc. E nd modification: Chol (cholesterol), etc. |
Aptamer | Sugar Modification: 2'-OMe, 2'-NH2, 2'-F, LNA, etc. Base Modification: methylated cytosine (5-Me-dC), etc. Backbone Modification: PS (phosphorothioate) modification, etc. E nd modification: 3'-inverted thymidine, Chol (cholesterol), Biotin, Thiol, NH 2 , fluorescent dyes, etc. |
Others | Custom chemical modification and fluorescent labeling services |
Delivery System Customization and Conjugation Services:
Delivery System | Features | Services |
GalNAc (N-acetylgalactosamine) | GalNAc is the targeting ligand of the sialic acid receptor (ASGPR), which is mainly expressed on the surface of hepatic parenchymal cells. The conjugate of nucleic acid and GalNAc enters the cell through endocytosis to function. | Custom GalNAc Synthesis GalNAc-siRNA Synthesis GalNAc-ASO Synthesis GalNAc-miRNA Synthesis Customized design and synthesis of GalNAc delivery proposal |
Peptide | Peptides have better membrane permeability and strong resistance to degradation. Therefore, conjugating oligonucleotides with various biological functions to peptides can not only improve the biological activity of oligonucleotides but also enhance their cell permeability. | Peptide Synthesis (drug peptides, custom peptides, RGD cyclic peptides, etc.) Peptide-siRNA Conjugation Peptide-ASO Conjugation Peptide-DNA Conjugation RGD-siRNA Conjugation |
Lipid | LNP not only prevents degradation of delivered oligonucleotides and prolongs circulation time, but also facilitates oligonucleotide uptake, enhances intracellular transport, and facilitates endosomal escape. | LNP-siRNA Conjugation LNP-ASO Conjugation |
PEG (polyethylene glycol) | The half-life of PEG-modified ASO in the body is significantly prolonged, and PEG can reduce the excretion rate of oligonucleotides and promote the uptake of nucleic acid drugs by corresponding cells. | PEG-Aptamer Conjugation PEG-siRNA Conjugation PEG-ASO Conjugation |
Others | / | Custom delivery proposal design and synthesis |
